FINWIRES · TerminalLIVE
FINWIRES

EMEA Natural Gas Update: Prices Drop on Latest US-Iran Peace Proposal

By

-- European natural gas futures prices trimmed earlier declines in after-hours trade on Wednesday after Iran said it was reviewing a US proposal aimed at ending the conflict, signaling no immediate acceptance of terms pushed by Washington.

Dutch TTF futures fell 6.012% to 44.105 euros ($51.83), while UK NBP contracts fell 5.825% to 108.32 British pence ($1.47).

Prices had dropped by nearly 9% earlier in the session on initial reports of diplomatic progress before reversing some of those losses after US President Donald Trump threatened intensified military action if Tehran rejects the deal.

The White House reportedly believes a framework agreement is close and is awaiting Iran's response by Friday, news outlets reported. Late Tuesday, Trump said the US would pause a recently announced operation to escort commercial shipping through the Strait of Hormuz, citing "great progress" in talks. However, he later warned that if Iran rejects the proposal, "the bombing starts" and would be at a higher level of intensity than before.

The conflict in the Middle East and the closure of the Strait of Hormuz have kept European natural gas supplies tight and expensive. "Although most Middle East gas flows to Asia, the disruption has tightened global supply and raised concerns in Europe, which needs to rebuild inventories ahead of winter," Trading Economics said.

EU gas storage levels stood at 34.07% of capacity on Wednesday, according to Gas Infrastructure Europe, well below 41.4% a year earlier.

Separately, Norway's Equinor reported its strongest quarterly earnings in three years on Wednesday, supported by higher production and rising prices driven by the conflict. The company said the tensions in the Gulf have also increased Asian demand for LNG cargoes from Europe.

Equinor operates an LNG plant in Arctic Hammerfest, typically serving customers in Europe.

"But we see that there is demand from customers in Asia who contact us once a year to maintain their customer relationship. They call twice a week now," Equinor CEO Anders Opedal reportedly said during an earnings call.

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL